CapsoVision, Inc. (NASDAQ:CV) Short Interest Update

CapsoVision, Inc. (NASDAQ:CV) saw a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 429,030 shares, an increase of 19.9% from the January 29th total of 357,735 shares. Based on an average daily volume of 213,138 shares, the days-to-cover ratio is presently 2.0 days. Currently, 0.9% of the shares of the company are sold short. Currently, 0.9% of the shares of the company are sold short. Based on an average daily volume of 213,138 shares, the days-to-cover ratio is presently 2.0 days.

Hedge Funds Weigh In On CapsoVision

Several hedge funds have recently modified their holdings of the stock. Deutsche Bank AG bought a new position in shares of CapsoVision in the 4th quarter valued at about $47,000. Citadel Advisors LLC purchased a new stake in CapsoVision during the third quarter valued at approximately $115,000. State Street Corp lifted its stake in shares of CapsoVision by 340.7% in the 4th quarter. State Street Corp now owns 85,929 shares of the company’s stock valued at $919,000 after purchasing an additional 66,429 shares during the last quarter. New York State Common Retirement Fund purchased a new position in shares of CapsoVision in the 3rd quarter worth approximately $34,000. Finally, Virtu Financial LLC bought a new position in shares of CapsoVision during the 4th quarter valued at approximately $128,000.

CapsoVision Stock Down 2.5%

NASDAQ CV opened at $5.06 on Friday. CapsoVision has a twelve month low of $3.43 and a twelve month high of $15.37. The business has a 50-day moving average price of $6.27 and a 200-day moving average price of $5.97. The firm has a market cap of $237.01 million and a price-to-earnings ratio of -2.31.

Wall Street Analyst Weigh In

A number of brokerages have commented on CV. Wall Street Zen upgraded CapsoVision to a “hold” rating in a research report on Saturday, January 10th. Weiss Ratings reiterated a “sell (e)” rating on shares of CapsoVision in a research note on Monday, December 29th. Finally, Benchmark restated a “speculative buy” rating on shares of CapsoVision in a research note on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $6.00.

About CapsoVision

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.